ArticleFrontiers in bioengineering and biotechnology2021
Cathelicidin LL37 Promotes Osteogenic Differentiation
Article in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Hydrogel Implementing Drug Delivery in Cranial Bone Tissue Engineering.Journal of functional biomaterials · 2026Review
- Peptide-conjugated biodegradable polyester scaffolds for bone regeneration.Biomaterials · 2026Review
- The role of gelatin and collagen in cell viability and osteogenic potential of an injectable chitosan-based scaffold containing LL37 peptide.Research in pharmaceutical sciences · 2025Article
- Distribution of Immunomodulation, Protection and Regeneration Factors in Cleft-Affected Bone and Cartilage.Diagnostics (Basel, Switzerland) · 2024Article
- The EGCG and α-Mangosteen Stimulate SHED-IL10 and SHED-LL37 Metabolite Concentration.European journal of dentistry · 2024Article
- A Novel Lipopeptide-Functionalized Metal-Organic Framework for Periodontitis Therapy through the Htra1/FAK/YAP Pathway.Biomaterials research · 2024Article
- Long-Term Administration of LL-37 Can Induce Irreversible Rosacea-like Lesion.Current issues in molecular biology · 2023Article
- Research progress and future prospects of antimicrobial modified polyetheretherketone (PEEK) for the treatment of bone infections.Frontiers in bioengineering and biotechnology · 2023Review
- LL-37-Coupled Porous Composite Scaffold for the Treatment of Infected Segmental Bone Defect.Pharmaceutics · 2022Article
- Regulation of LL-37 in Bone and Periodontium Regeneration.Life (Basel, Switzerland) · 2022Review
- Bioinspired synthetic peptide-based biomaterials regenerate bone through biomimicking of extracellular matrix.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Different types of biomaterials have been used to repair the defect of bony orbit. However, exposure and infections are still critical risks in clinical application. Biomaterials with characteristics of osteogenesis and antibiosis are needed for bone regeneration. In this study, we aimed to characterize the antimicrobial effects of cathelicidin-LL37 and to assess any impacts on osteogenic activity. Furthermore, we attempted to demonstrate the feasibility of LL37 as a potential strategy in the reconstruction of clinical bone defects. Human adipose-derived mesenchyme stem cells (hADSCs) were cultured with different concentrations of LL37 and the optimum concentration for osteogenesis was selected for further
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.